摘要
目的评价慢性阻塞性肺疾病急性加重期患者应用布地奈德联合复方异丙托溴铵雾化吸入治疗效果及对其肺功能的影响。方法80例慢性阻塞性肺疾病急性加重期患者作为研究对象,根据治疗方法不同分为观察组与对照组,各40例。对照组患者实施常规治疗,观察组患者在常规治疗的基础上给予复方异丙托溴铵联合布地奈德雾化吸入治疗。比较两组患者治疗前及治疗后1周肺功能指标水平;比较两组患者临床治疗效果;比较两组患者不良反应发生情况。结果治疗前,两组患者第1秒用力呼气容积(FEV1)、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)、呼气峰流速(PEF)、最大呼气中期流速(MMEF)水平比较差异无统计学意义(P>0.05);治疗后1周,观察组患者FEV1、FEV1/FVC、PEF、MMEF水平均明显高于对照组,差异具有统计学意义(P<0.05)。观察组患者临床治疗总有效率为87.50%,明显高于对照组的55.00%,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为5.00%,明显低于对照组的20.00%,差异具有统计学意义(P<0.05)。结论慢性阻塞性肺疾病急性加重期患者经布地奈德联合复方异丙托溴铵雾化吸入治疗,可以有效改善患者的肺功能,促进支气管平滑肌扩张,改善气道痉挛和局部感染,对患者病情的控制起到明显的促进作用。
Objective To evaluate the effect of budesonide combined with aerosol inhalation of compound ipratropium bromide in patients with acute exacerbation of chronic obstructive pulmonary disease and its influence on pulmonary function. Methods A total of 80 patients with acute exacerbation of chronic obstructive pulmonary disease as study subjects were divided by different treatment methods into observation group and control group, with 40 cases in each group. The control group received conventional therapy, and the observation group was treated with budesonide combined with aerosol inhalation of compound ipratropium bromide on the basis of conventional therapy. Comparison were made on pulmonary function indexes before treatment and 1 week after treatment, clinical treatment effect and occurrence of adverse reactions between the two groups. Results Before treatment, there was no statistically significant difference in forced expiratory volume in the first second(FEV1), FEV1/forced vital capacity(FEV1/FVC), peak expiratory flow(PEF) and maximum mid-expiratory flow(MMEF) between the two groups(P>0.05). After 1 week of treatment, the observation group had obviously higher FEV1, FEV1/FVC, PEF and MMEF than the control group, and the difference was statistically significant(P<0.05). The observation group had obviously higher total effective rate of clinical treatment as 87.50% than 55.00% in the control group, and the difference was statistically significant(P<0.05). The observation group had obviously lower incidence of adverse reactions as 5.00% than 20.00% in the control group, and the difference was statistically significant(P<0.05). Conclusion Budesonide combined with aerosol inhalation of compound ipratropium bromide can effectively improve the pulmonary function of patients with acute exacerbation of chronic obstructive pulmonary disease, promote the expansion of bronchial smooth muscle, improve airway spasm and local infection, and play a significant role in promoting disease control.
作者
陈绍山
林士军
朱日飞
李炽观
CHEN Shao-shan;LIN Shi-jun;ZHU Ri-fei(Shenzhen Longgang District People’s Hospital,Shenzhen 518116,China)
出处
《中国现代药物应用》
2019年第14期3-5,共3页
Chinese Journal of Modern Drug Application
关键词
慢性阻塞性肺疾病
急性加重期
布地奈德
复方异丙托溴铵
雾化吸入
肺功能
Chronic obstructive pulmonary disease
Acute exacerbation
Budesonide
Compound ipratropium bromide
Aerosol inhalation
Pulmonary function
